The local anaesthetic used so often, in so many forms, that its dose limits are the ones most likely to be assumed rather than checked.
Lidocaine is arguably the single most versatile drug in anaesthesia practice — a local infiltration agent, a nerve block agent, a topical airway anaesthetic, an IV infusion for analgesia and antiarrhythmic control, and a mainstay of dental and dermatological practice well beyond the OR. That versatility is also its risk: because it is used so often, in so many concentrations and routes, the maximum safe dose is the number most likely to be assumed correct from memory rather than actually calculated for the patient in front of you. Here is what matters about it, from the receptor up to the bedside.
Lidocaine is an amide local anaesthetic — distinguished from the older ester local anaesthetics (procaine, chloroprocaine, tetracaine) by the amide linkage between its aromatic ring and amine group, which determines both its metabolic pathway and its allergic potential.
Voltage-gated sodium channels (neuronal): lidocaine's primary anaesthetic action is reversible blockade of voltage-gated sodium channels on the inner surface of the neuronal membrane, preventing the influx of sodium required for action potential propagation. This blocks nerve conduction along the affected fibre without permanently damaging it — the basis of all local and regional anaesthetic technique.
Fibre-selective blockade: smaller, unmyelinated or lightly myelinated fibres (C fibres carrying pain and temperature) are blocked before larger, heavily myelinated fibres (A-alpha carrying motor and proprioception) — the pharmacological basis of "differential blockade," where pain sensation is lost before touch, and touch before motor power, at a given concentration.
Cardiac sodium channels: the same sodium-channel blockade underlies lidocaine's Vaughan Williams Class Ib antiarrhythmic action — it shortens the action potential duration and preferentially suppresses conduction in ischaemic or depolarised myocardial tissue, which is why it has a long history as a ventricular antiarrhythmic, and also why systemic overdose produces the cardiotoxicity central to local anaesthetic systemic toxicity (LAST).
Lidocaine's pKa (~7.9) sits close enough to physiological pH that a clinically useful fraction of the drug exists in the uncharged, lipid-soluble form capable of crossing the neuronal membrane — this is why lidocaine has one of the fastest onset times among commonly used local anaesthetics. Once inside the axon, re-ionisation to the charged form is what actually blocks the sodium channel from the cytoplasmic side. Alkalinisation of a lidocaine solution (adding sodium bicarbonate) increases the proportion of unionised drug and can meaningfully speed onset — a technique used in some nerve block and infiltration protocols.
Lidocaine is metabolised almost entirely in the liver, via a pathway that is fast and efficient in a healthy patient but becomes a real limiting factor in hepatic impairment or reduced hepatic blood flow.
| Parameter | Value | Clinical relevance |
|---|---|---|
| Onset (infiltration) | ~5–15 min (peak effect) | Faster with alkalinisation; slower in inflamed or acidic tissue |
| Onset (IV) | ~1–2 min | Relevant for IV lidocaine analgesia/antiarrhythmic use |
| Duration (plain, infiltration) | ~30–120 min | Shorter than bupivacaine or ropivacaine; not ideal for prolonged procedures |
| Duration (with epinephrine) | ~60–180 min | Vasoconstriction slows systemic absorption, prolongs local effect, raises the safe maximum dose |
| Elimination half-life | ~1.5–2 hours | Prolonged significantly in hepatic impairment or reduced hepatic perfusion (e.g. heart failure, shock) |
| Protein binding | ~60–80% (mainly alpha-1 acid glycoprotein) | Acute illness raises AAG and can lower free fraction; the reverse is also clinically relevant |
| Metabolism | Hepatic (CYP3A4/CYP1A2), to active metabolites MEGX and GX | MEGX retains some pharmacologic activity and toxicity potential, particularly with prolonged infusion |
| Excretion | Renal, as metabolites (<10% unchanged) | Renal impairment has less direct effect on clearance than hepatic impairment |
At therapeutic local anaesthetic and antiarrhythmic doses, lidocaine has minimal direct cardiovascular effect and a good safety margin. At toxic plasma concentrations, however, it produces dose-dependent cardiotoxicity — sodium channel blockade in the myocardium slows conduction, widens the QRS complex, and can progress to bradyarrhythmias, ventricular arrhythmias, and eventually cardiovascular collapse. This progression, and the specific management it requires, is the core of local anaesthetic systemic toxicity, addressed in detail below.
CNS effects are typically the earliest warning sign of rising plasma concentration, occurring before overt cardiotoxicity in the classic teaching (though the two can occur close together, and cardiac collapse can occasionally precede clear CNS signs). Early signs include perioral numbness, a metallic taste, tinnitus, and lightheadedness; as concentration rises, this can progress to visual disturbance, slurred speech, muscle twitching, and ultimately generalised seizures. At sub-toxic systemic concentrations (as with IV lidocaine infusion), the drug has genuine analgesic, antihyperalgesic, and anti-inflammatory properties independent of any local nerve block.
Minimal direct respiratory depressant effect at standard local anaesthetic doses. As a topical agent for airway anaesthesia, however, lidocaine can blunt protective airway reflexes (cough, gag) sufficiently to increase aspiration risk if used liberally before airway instrumentation in a patient who has not been adequately fasted or whose airway is not otherwise secured.
Genuine antitussive and anti-inflammatory properties at systemic sub-toxic doses, part of the basis for IV lidocaine's use in enhanced recovery and multimodal analgesia protocols. No clinically significant effect on uterine tone. Methaemoglobinaemia is a recognised but uncommon complication, more classically associated with prilocaine and benzocaine but reported with high-dose or repeated topical lidocaine exposure, particularly in infants and in patients with G6PD deficiency or other predisposing conditions.
Few drugs in the anaesthetic cupboard cross as many domains as lidocaine — local infiltration, regional and neuraxial blockade, topical airway anaesthesia, IV analgesia, and cardiac rhythm control all draw on the same core pharmacology.
The standard agent for minor procedures, wound closure, and pre-emptive skin anaesthesia before line or block placement.
Used alone for shorter procedures or in combination with a longer-acting agent (bupivacaine, ropivacaine) to combine fast onset with extended duration.
Spinal and epidural use, particularly where a shorter duration procedure or rapid onset is prioritised over the longer block of bupivacaine.
Nebulised, sprayed, or gargled lidocaine is a mainstay for awake fibreoptic intubation and awake airway procedures, anaesthetising the oropharynx, larynx, and trachea while preserving spontaneous ventilation.
Used intraoperatively and postoperatively as an opioid-sparing analgesic and anti-inflammatory adjunct, particularly within enhanced recovery protocols for abdominal surgery.
IV lidocaine given shortly before laryngoscopy blunts the cough and haemodynamic response to intubation, useful in neurosurgical, ophthalmic, and cardiac cases where a surge in intracranial, intraocular, or blood pressure is undesirable.
A second-line agent for ventricular arrhythmias, including in the ACLS pulseless VT/VF algorithm when amiodarone is unavailable or has failed.
A standard agent for IV regional anaesthesia of a limb under tourniquet control for short procedures.
| Indication | Dose | Notes |
|---|---|---|
| Local infiltration (plain) | Maximum 4.5 mg/kg, up to 300 mg total | Calculate before injecting; do not assume a "standard" volume is within limits for a smaller patient |
| Local infiltration (with epinephrine) | Maximum 7 mg/kg, up to 500 mg total | Epinephrine slows systemic absorption, permitting the higher ceiling — the ceiling applies to the combination, not an independent allowance |
| Topical (airway/mucosal) | Contributes to the same total-dose ceiling as any other route | Topical and nebulised doses are genuinely absorbed systemically — easy to under-count against the total maximum |
| IV bolus (attenuating intubation response) | 1–1.5 mg/kg IV, 1–3 min before laryngoscopy | Counts toward total dose if local anaesthetic is also being used elsewhere in the same case |
| IV infusion (analgesia/ERAS) | Bolus 1–1.5 mg/kg, then infusion 1–2 mg/kg/h | Typically discontinued at end of surgery or within 24 h; institutional protocols vary |
| Antiarrhythmic (ACLS, pulseless VT/VF) | 1–1.5 mg/kg IV bolus, may repeat 0.5–0.75 mg/kg | Follow current ACLS algorithm and local resuscitation council guidance for exact sequencing |
| Paediatric infiltration | Maximum 4.5 mg/kg (plain); reduce further in infants <6 months | Weight-based calculation essential; do not extrapolate from adult "typical" volumes |
Doses are illustrative and reflect commonly cited ranges in the anaesthesia and emergency medicine literature. Always confirm against your institution's protocol, current product labelling, and current resuscitation council guidance — dosing in this table is not a substitute for local guidelines.
When lidocaine is used in more than one place in the same case — infiltration at a line site, topicalisation of the airway, and a nerve block, for example — every route counts toward the same total maximum dose for that patient. It is a common and entirely avoidable error to calculate each site's dose in isolation and lose track of the cumulative total. Calculate the patient's maximum allowable dose in milligrams before the case starts, and track what has actually been given against it as the case proceeds.
LAST results from excessive plasma concentration of local anaesthetic, most often from inadvertent intravascular injection or an absolute dose exceeding the safe maximum. Early signs are typically CNS — perioral numbness, metallic taste, tinnitus, agitation, or confusion — and can progress rapidly to seizures, arrhythmias, and cardiovascular collapse; presentation can occasionally be atypical, with cardiovascular signs appearing first or in isolation. Management follows the current ASRA LAST checklist: stop injecting the local anaesthetic immediately, call for help, manage the airway with 100% oxygen, control seizures preferably with a benzodiazepine, and alert the nearest facility with cardiopulmonary bypass capability if cardiovascular instability develops. Intravenous lipid emulsion (20%) should be given at the first signs of significant toxicity: for patients ≥70 kg, a 100 mL bolus followed by the remainder of a 250 mL bag infused over roughly 15 minutes; for smaller patients, a weight-based 1.5 mL/kg bolus, up to a maximum total dose around 12 mL/kg. If cardiac arrest occurs, standard ACLS is modified — epinephrine doses should be kept small (≤1 mcg/kg) rather than standard resuscitation doses, and vasopressin, calcium-channel blockers, beta-blockers, and other local anaesthetics should be avoided. Confirm the current version of the checklist at your institution, as specific figures are periodically revised.
Lidocaine is used extensively in paediatric anaesthesia and emergency medicine, but the combination of a smaller total safe dose and less physiological reserve makes careful weight-based calculation especially important.
The textbook version of lidocaine use is a quick calculation, a clean injection, and a predictable block or numbness with no further thought required. The bedside version has more texture than that.
The first thing worth building as a habit is doing the maximum-dose calculation before the syringe is drawn up, not after — and doing it again if the plan changes mid-case, such as adding a nerve block after infiltrating a line site. It is easy, particularly in a long or multi-step case, to lose an accurate running total of exactly how much lidocaine has actually gone into the patient across several small doses given at different points, by different people, at different times.
The second thing is that topical and nebulised doses for airway anaesthesia are genuinely absorbed and genuinely count. It is tempting to treat spray-as-you-go topicalisation during an awake fibreoptic intubation as somehow separate from "real" dosing, but a mucosal surface as vascular as the oropharynx and trachea absorbs local anaesthetic efficiently — the running total from an awake airway case can climb further than expected if each spray isn't being tracked against the same total-dose ceiling as everything else given.
The third thing is that early signs of toxicity are subtle and easy to attribute to something else — a patient reporting a metallic taste or ringing in the ears during a slow infiltration or block can be dismissed as anxiety or as an unrelated complaint, when it is in fact the first warning that plasma concentration is rising. Taking those early symptoms seriously, stopping the injection, and reassessing before proceeding further costs very little time and closes off the entire downstream risk of progressing to seizure or cardiovascular compromise.
Lidocaine's greatest risk is not an unusual reaction in an unusual patient — it is the ordinary, cumulative arithmetic error of a familiar drug used in several small doses across a single case without a running total. Calculate the maximum dose before starting, track every route against that same ceiling, and treat early CNS symptoms as a genuine early-warning sign rather than an incidental complaint.
Because lidocaine is used so often and so safely at ordinary doses, it is easy to stop treating each administration as a deliberate calculation and start treating it as routine. Most lidocaine given in clinical practice is genuinely low-risk. The cases that go wrong are rarely dramatic outliers — they are typically the predictable result of an uncounted cumulative dose across multiple sites or routes in the same patient, in the same case. The fix is not caution in the abstract; it is a specific habit of arithmetic, applied every time.
This content is intended for educational reflection and discussion among clinicians and trainees. Dosing information reflects commonly cited ranges in the anaesthesia, regional anaesthesia, and resuscitation literature and is not a substitute for institutional protocols, current product labelling, current ASRA/resuscitation council guidance, or independent clinical judgment. The views expressed are the author's own and do not represent any institution, employer, or training program.